Cardiol Therapeutics (CRDL) Competitors C$1.83 -0.02 (-1.08%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock CRDL vs. DNA, AIM, VBV, CUS, ITH, FRX, IPA, APM, GXE, and GPHShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Dalradian Resources (DNA), Aimia (AIM), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), International Tower Hill Mines (ITH), Fennec Pharmaceuticals (FRX), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), and Graphite One (GPH). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. Its Competitors Dalradian Resources Aimia VBI Vaccines Chemtrade Electrochem Inc, International Tower Hill Mines Fennec Pharmaceuticals ImmunoPrecise Antibodies Andean Precious Metals Gear Energy Graphite One Dalradian Resources (TSE:DNA) and Cardiol Therapeutics (TSE:CRDL) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings. Is DNA or CRDL more profitable? Dalradian Resources' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dalradian ResourcesN/A N/A N/A Cardiol Therapeutics N/A -195.07%-54.15% Do insiders & institutionals hold more shares of DNA or CRDL? 11.4% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to DNA or CRDL? In the previous week, Cardiol Therapeutics' average media sentiment score of 0.47 beat Dalradian Resources' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Dalradian Resources Neutral Cardiol Therapeutics Neutral Which has better valuation & earnings, DNA or CRDL? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Dalradian Resources, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDalradian ResourcesN/AN/AN/A-C$0.03N/ACardiol TherapeuticsN/AN/A-C$42.93M-C$0.51-3.60 SummaryCardiol Therapeutics beats Dalradian Resources on 4 of the 7 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$151.85MC$2.21BC$5.68BC$6.37BDividend YieldN/A2.92%4.61%6.72%P/E Ratio-3.604.1530.6867.48Price / SalesN/A614.91464.101,639.76Price / Cash0.9810.3738.2183.29Price / Book12.2511.098.994.88Net Income-C$42.93MC$20.70BC$3.25BC$301.20M7 Day Performance30.71%2.78%4.78%1.12%1 Month Performance5.17%5.49%6.80%2.43%1 Year Performance-34.64%3.08%30.61%28.14% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol TherapeuticsN/AC$1.83-1.1%N/A-31.7%C$151.85MN/A-3.6020News CoverageHigh Trading VolumeDNADalradian ResourcesN/AN/AN/AN/AC$519.02MN/A-56.15640AIMAimia2.5218 of 5 starsC$3.24+4.5%C$4.00+23.5%+20.9%C$311.61MC$464.71M-3.9920News CoverageHigh Trading VolumeVBVVBI VaccinesN/AN/AN/AN/AC$308.86MC$3.36M-4.9722CUSChemtrade Electrochem Inc,N/AN/AN/AN/AC$306.50MN/A0.0060ITHInternational Tower Hill MinesN/AC$1.78-4.3%N/A+186.7%C$249.91MN/A-74.37220Gap UpFRXFennec PharmaceuticalsN/AC$12.51-1.5%N/A+56.3%C$241.25MC$34.86M-211.9210News CoverageIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownAPMAndean Precious Metals3.054 of 5 starsC$1.29+7.5%C$2.00+55.0%+22.9%C$135.47MC$154.78M2.5530GXEGear EnergyN/AN/AN/AN/AC$126.52MC$134.93M10.391,310GPHGraphite OneN/AC$0.96-4.0%N/A+21.0%C$97.20MN/A-13.8020Gap Down Related Companies and Tools Related Companies Dalradian Resources Alternatives Aimia Alternatives VBI Vaccines Alternatives Chemtrade Electrochem Inc, Alternatives International Tower Hill Mines Alternatives Fennec Pharmaceuticals Alternatives ImmunoPrecise Antibodies Alternatives Andean Precious Metals Alternatives Gear Energy Alternatives Graphite One Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:CRDL) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access